Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2003

View Archived Issues

TolerRx raises funds for development of two lead products and research programs

Avant awarded SBIR grant for Ty800 development

GSK launches Pediarix in the U.S.

Three series of telomerase inhibitors recently presented by Kyowa Hakko

Newly identified antibacterial quinolizines covered by Sato patent

Wyeth researchers identify novel series of estrogenic compounds

Wyeth claims new oxytocin antagonists with utility in preterm labor

Aventis to develop novel cancer targets under Eos collaboration

Bayer acquires antibody license from MorphoSys

BioFocus and Amgen form ion channel drug discovery collaboration

Collegium enters antibody licensing agreement with Tufts for HUS

Centagenetix and Elixir to merge

King completes acquisition of Meridian Medical Technologies

Mera to acquire Ancile

Takeda and Beth Israel Deaconess collaborate on metabolic diseases

Epimmune cleared to begin phase I/II trials of EP-2101

PI-166 enters phase Ib trial for liver cancer

First U.S. clinical trial of Rigel antiallergy drug

Enzon suspends PEG-paclitaxel development program

NIH grant to support development of UC-781

Approval of Coreg recommended for heart attack patients with impaired cardiac function

Carbazole-based NPY Y5 modulators jointly reported by Boehringer Ingelheim and Novo Nordisk

Novel series of NAALADase inhibitors recently claimed by Guilford

Chronic tacrolimus nephrotoxicity suppressed by NF-kB inhibitor

Efficacy of teriparatide unaffected by age, BMD or number of fractures

Potential use of AMG-073 in dialysis patients with secondary hyperparathyroidism

Analgesic effects of a potent and selective P2X3 and P2X2/3 receptor antagonist

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...